225results about "Polypeptide with affinity tag" patented technology

The invention provides a plug-and-play Mi3 protein nanocage fusion protein with a VNP6 tag and a preparation method and application of the plug-and-play Mi3 protein nanocage fusion protein, the fusion protein comprises the VNP6 tag, a SpyCatch003 component, a Mi3 protein nanocage and a functional protein sequence, and the VNP6 tag is located at the N end of the fusion protein. The VNP6 peptide sequence or the variant thereof is utilized to induce a vesicle or vesicle-like structure beneficial to protein folding and stabilization in escherichia coli, so that the correct folding rate and activity of recombinant protein are improved while the overall intracellular molecular crowding effect is relieved. The core idea of the invention lies in that the internal structure of cells is regulated at low temperature, and the internal microenvironment of an escherichia coli expression system is optimized, so that protein molecules under high expression load can obtain more reasonable spatial distribution, and the problems of misfolding and aggregation caused by molecular crowding are reduced.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

Disclosed herein are immune cells expressing engineered cytokine receptor switches which, upon activation, can direct differentiation of the immune cells. The present disclosure further provides compositions and methods for transfecting, expanding, and activating these immune cells, including substrates which activate the engineered cytokine receptor switches disclosed herein.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. A preferred peptide includes the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. The peptides include the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

The present invention relates to an artificially engineered CRISPR / Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR / Cas9 system including the same enzyme in genome and / or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Provided herein are compositions, systems, and methods for delivering an effector protein into a cell. The present disclosure, in some aspects, provide novel proteins delivering an effector protein into a cell. The novel proteins are supernegatively charged proteins derived from highly anionic proteins identified from the proteome (e.g., human proteome). The novel protein tags can be associated (e.g., covalently or nocovalently) with the protein to be delivered to facilitate delivery of the effector protein into a cell.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.

The present application is directed to multiplex intein-based methods and compositions for the generation engineered cells expressing modular polypeptides, for example CARs and CCRs.

Provided is a method for producing a heterodimeric protein such as a bispecific antibody with which a heterodimeric protein composed of only domains having natural amino acid sequences can also be produced. A production method of the present invention is a method for producing a heterodimeric protein. The production method includes a production step of producing a heterodimeric protein by reacting a dimeric protein having a reaction tag with a modification protein for modifying the dimeric protein. The dimeric protein having a reaction tag includes a first monomeric protein and a second monomeric protein. The first monomeric protein includes a first reaction tag and a first dimer formation domain capable of forming a dimer in this order. The first reaction tag includes a binding tag and a first C intein. The second monomeric protein includes a second reaction tag and a second dimer formation domain capable of forming a dimer together with the first dimer formation domain in this order. The second reaction tag includes a binding partner capable of binding to the binding tag, and a second C intein. The modification protein includes a first modification protein and a second modification protein. The first modification protein includes a first N intein capable of reacting with the first C intein, and a first addition component to be added to the first monomeric protein. The second modification protein includes a second N intein capable of reacting with the second C intein, and a second addition component to be added to the second monomeric protein. The first addition component and the second addition component are different addition components. The first monomeric protein and the second monomeric protein form a dimer. In the production step, the first N intein of the first modification protein reacts with the first C intein of the first monomeric protein, and then the first addition component of the first modification protein is linked to the first monomeric protein, and the second N intein of the second modification protein reacts with the second C intein of the second monomeric protein, and then the second addition component of the second modification protein is linked to the second monomeric protein.

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

The present invention relates to novel enzyme nanoparticles capable of converting methane into methanol, in which key active sites of methane-oxidizing bacteria are fused with each other and expressed on a protein that can be self-assembled in cells to form nanoparticles, and specifically to enzyme nanoparticles including a protein having methane monooxygenase (MMO) activity and active sites of the methane oxidase, a method for production thereof, a recombinant microorganism into which a nucleic acid encoding the protein and the active site of the methane oxidase is introduced, and immobilized enzyme nanoparticles including the enzyme nanoparticles loaded on a carrier.

The present invention relates to an anti-IL-8 antibody. Specifically, the present invention provides an antibody heavy chain variable region, wherein the heavy chain variable region includes the following three complementary determining regions (CDRs): CDR1 as shown in SEQ ID NO: 1, CDR2 as shown in SEQ ID NO: 2, and CDR3 as shown in SEQ ID NO: 3. The antibody of the present invention can bind to IL-8 with high affinity and block or inhibit IL-8-induced activities, such as pro-inflammatory activity, chemotactic activity and angiogenesis, to treat immune, autoimmune, inflammatory or infectious diseases and cancers associated with IL-8.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

A peptide comprising the sequence shown below is added as a peptide tag to a useful protein, followed by allowing its expression.Xm(PYn)qPZr In this formula, X, Y, and Z each represent an amino acid residue independently selected from the group consisting of R, G, S, K, T, L, N, Q, and H, with the proviso that at least one Y represents K, L, N, Q, H, or R. m represents an integer of 0 to 5; n represents 1, 2, or 3; q represents an integer of 1 to 10; and r represents an integer of 0 to 10.

Provided are a Cas effector protein, a fusion protein containing said protein, and a nucleic acid molecule coding same. Also provided are a complex and a composition for nucleic acid editing, for example, a complex and a composition for gene or genome editing, containing the Cas effector protein or the fusion protein, or the nucleic acid molecule encoding same. Also provided is a method for nucleic acid editing, for example, a method for gene or genome editing, using the Cas effector protein or the fusion protein.

The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.

Disclosed are hypersensitive-response eliciting peptides and non-hypersensitive response eliciting peptides that induce active plant responses, and that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post- harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.

There is provided a composition for modifying a T cell, the composition comprising: a protein complex comprising a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain; a guide oligonucleotide specific to a T cell receptor constant (TRAC) gene of the T cell; and a donor DNA comprising two homology arms at each end of the donor DNA homologous to exon1 of the TRAC gene and encoding therebetween a chimeric antigen T cell receptor comprising: a translocation signal for translocation to a cell membrane of the T cell; a transmembrane domain; an intracellular signaling domain; and an extracellular antigen binding domain.

The present invention relates to the use of a DNA glycosylase enzyme for removing or blocking uracil containing polynucleotides, and methods incorporating the use of such enzymes to remove or block uracil containing polynucleotides from polynucleotide containing compositions, particularly in methods of template-free DNA synthesis The present invention further relates to methods of tethering polynucleotides to a surface or molecule using a DNA glycosylase enzyme, the resulting products therefrom, and to modified DNA glycosylase enzymes.

Provided herein are compositions and methods for the treatment of infectious diseases including COVID and Long COVID. The compositions and methods can be used to treat symptoms relating to infectious disease infection or vaccination as well as for immune system response enhancement to infection and vaccination. A composition includes Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) proteins and / or nucleic acids or functional fragments thereof. A method includes the treatment of infectious diseases such as COVID and long COVID, and for enhancement of immunogenic response to infectious diseases using the compositions disclosed herein.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present application relates to the field of biological medicine and clinical diagnosis, and more particularly, the present application relates to a polypeptide having binding affinity to AXL protein and application thereof; the polypeptide has binding affinity to AXL protein, and therefore can be used for detecting AXL protein, so that the polypeptide has diagnostic or therapeutic use as a drug or molecular targeting reagent.

A process for synthesizing and separating secretory IgA from a mixture of IgA monomer and IgA dimer is provided The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and then binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is provided. A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric.